We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mantle cell lymphoma: HIGH-DOSE CYTARABINE (ARA-C) IMPROVES OS.
- Authors
Duggan, Peter
- Abstract
The article discusses the efficacy of rituximab followed by a high-dose cytarabine containing myeloablative regimen and autologous stem cell transplantation (ASCT) for the treatment of mantle cell lymphoma (MCL). The MCL net has demonstrated that myeloablative consolidation followed by ASCT resulted in a prolongation of progression-free survival (PFS). In addition, Phase II studies suggest that the addition of rituximab or high dose of cytarabine improves outcome.
- Subjects
LYMPHOMA treatment; RITUXIMAB; CYTARABINE; TREATMENT effectiveness; DRUG efficacy; STEM cell transplantation
- Publication
Oncology Exchange, 2013, Vol 12, Issue 1, p41
- ISSN
1705-2394
- Publication type
Article